Valuation: Terns Pharmaceuticals, Inc.

Market Cap 6.11B 5.43B 5.08B 4.63B 8.71B 589B 8.83B 61.43B 23.78B 300B 22.95B 22.46B 963B P/E 2024
-4.96x
P/E 2025 -39.1x
Enterprise Value 5.1B 4.53B 4.23B 3.86B 7.26B 491B 7.36B 51.2B 19.82B 250B 19.13B 18.72B 803B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.75%
Yield 2024 *
-
Yield 2025 -
1 day+0.04%
6 months+0.30%
Current year+31.06%
Current year 33.43
Extreme 33.43
53.19
1 year 6.98
Extreme 6.985
53.19
3 years 1.86
Extreme 1.865
53.19
5 years 1.45
Extreme 1.45
53.19
10 years 1.45
Extreme 1.45
53.19
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 46 2023-04-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 2022-01-05
Director TitleAgeSince
Director/Board Member 60 2026-05-04
Director/Board Member - 2026-05-04
Director/Board Member - 2026-05-04
Date Insider Type Main position Quantity % Market Cap. Importance
5/5/26 Tender

Chief Financial Officer

-996,753 0.8628%
5/5/26 Tender

Chief Executive Officer

-2,810,467 2.4329%
5/5/26 Issuer sale

Director

-91,697 0.0794%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-.--%+577.98%+952.68% 6.11B
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.07%-1.49%+24.49%+78.29% 59.26B
+1.09%-0.28%+4.65%+34.98% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.46%-0.47%+105.39%+233.99% 39.86B
Weighted average by Cap. +0.03%-0.31%+66.04%+158.21%

Financials

2024 2025
Net sales - -
Net income -88.85M -78.92M -73.8M -67.25M -127M -8.55B -128M -893M -346M -4.36B -334M -326M -13.99B -96.21M -85.45M -79.91M -72.82M -137M -9.26B -139M -967M -374M -4.72B -361M -353M -15.15B
Net Debt -357M -317M -296M -270M -508M -34.35B -515M -3.59B -1.39B -17.5B -1.34B -1.31B -56.2B -1.02B -904M -846M -771M -1.45B -98.02B -1.47B -10.23B -3.96B -49.92B -3.82B -3.74B -160B
Logo Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. is a clinical-stage oncology company. It has multiple drug candidates with the potential to deliver improved clinical outcomes in the target indication as either single-agent or combination therapies. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in the pipeline include TERN-701, TERN-501 and TERN-801. TERN-701 is a novel, oral allosteric BCR-ABL1 inhibitor with best-in-disease potential for chronic myeloid leukemia (CML) currently in Phase 1/2 development. Also, we have ongoing discovery efforts for small-molecule oncology candidates with undisclosed targets and indications. TERN-501 is a thyroid hormone receptor beta (THR-B) against high metabolic dysfunction-associated steatohepatitis (MASH) and obesity. TERN-801 is a Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist development candidate for obesity.
Employees
59
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. TERN Stock